Changing from synthetic implants to biologics is a natural, transformative and an increasingly common phenomenon in modern medicine. AmnioClear™ is an allograft biologic covering, which is shaped to cover wounds in various clinical situations including wound care, general surgery, musculoskeletal care and OB/GYN cases.
AmnioClear™ is the natural allograft alternative to porcine, bovine or polymer coverings. Derived from human placental material, AmnioClear™ is rich in human collagen endogenous proteins and peptides and is precisely compatible with the needs of a healing human body.
Processed by MTF – the leader in human tissue processing – under contract from AFCell Medical, AmnioClear™ delivers unparalleled safety and efficacy to the physician. MTF's unique and proprietary processing methods are recognized throughout the U.S. as meeting the highest standards for safety and efficacy.
April 17, 2013
AFcell Medical Hires Chief Operating Officer - Former Integra Life Sciences, Synovis Surgical Executive Joins Firm
AFcell Medical, the leading innovator and designer of surgical birth tissue forms as marketed under its AmnioClear brand, is proud to announce the hiring of David Buche as Chief Operating Officer.
August 27, 2012
AFcell Medical Reports Results from the Retrospective Study of a Novel Allograft Membrane to Prevent Post-Operative Adhesions in the Repair of Peroneal and Posterior Tibial Tendons
AFcell Medical announced the results of a retrospective study of the use of an amnion based allograft membrane to prevent post-operative adhesions between the tendon, peritendonous structures and overlying skin. Of the fourteen study patients, 86% were clear of adhesions anywhere around the surgery site and 93% were adhesion free at the tendon repair site 1.7 years post-surgery, on average, and of those patients with signs of adhesions the effects were rated mild or moderate.